Bristol-Myers Squibb stock has delivered a strong 42.2% return over the past year, while the current valuation checks show a mixed picture and the Discounted Cash Flow (DCF) intrinsic value estimate points to the shares trading at a sizeable discount to that model.

• The 42.2% one year return sets a high bar for new buyers, since a lot of optimism can already be reflected in the current share price.
• The expanded use of Nvidia powered AI systems for drug discovery may support expectations for future cash flows, while execution risk around large R&D investments and complex clinical outcomes can still affect how much of that value actually materialises.
• The company screens as undervalued on 4 out of 6 checks, which is a mixed set of signals rather than a clear bargain or clear overvaluation on the broader tests. You can see the breakdown in the 4 out of 6 score.

The issue now is whether Bristol-Myers Squibb's recent share price strength already reflects its intrinsic value, or if the DCF estimate of undervaluation still leaves meaningful upside on the table.

Is Bristol-Myers Squibb Still Cheap on Cash Flow?

The Discounted Cash Flow model for Bristol-Myers Squibb uses projected free cash flows to estimate what the stock might be worth today. On this basis, the latest twelve-month free cash flow sits at about $12 billion, with the model assuming a broadly declining path for future cash flows rather than aggressive growth. Even under those tempered assumptions, the intrinsic value is calculated at about $123 per share.

That compares to the current share price, which implies the stock trades at about a 48.1% discount to the modeled value. On this cash flow view, Bristol-Myers Squibb appears materially undervalued. The recent expansion of AI-driven drug discovery work with Nvidia helps explain why some investors see room for future productivity gains, even though the DCF already incorporates conservative long-term free cash flow projections.

Overall, the Discounted Cash Flow view indicates that Bristol-Myers Squibb stock appears undervalued relative to the cash it is expected to generate.

Our Discounted Cash Flow (DCF) analysis suggests Bristol-Myers Squibb is undervalued by 48.1%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Does Bristol-Myers Squibb Look Fairly Valued on Earnings?

P/E is a useful way to look at Bristol-Myers Squibb because earnings remain a key focus for investors in large pharmaceutical stocks. Right now, Bristol-Myers Squibb trades on a P/E of about 17.9x. That sits above the broader pharmaceuticals industry average of about 15.2x, yet still below the peer group average of roughly 27.9x.

The tailored fair P/E for Bristol-Myers Squibb is estimated at about 19.3x, based on factors such as its profitability profile, size and risk. The current 17.9x multiple sits a little below that fair level. This suggests the stock is not flagging as clearly cheap or expensive on earnings alone and instead looks broadly in line with what this framework would suggest.

Overall, Bristol-Myers Squibb looks roughly fairly valued on its P/E multiple.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Bristol-Myers Squibb pick up where the valuation checks leave off and explain which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today's price. Each narrative links a specific fair value to a clear story about Bristol-Myers Squibb's potential catalysts and risks, so you can see over time which version of events is actually unfolding on the Community page.

Bristol-Myers Squibb now splits the community, with one camp leaning into the pipeline and margin story while the other keeps its focus on execution and patent risk.

Bull case: 15% undervalued

"Breakthrough partnerships such as the BioNTech deal position BMS's pipeline for industry leadership in immuno-oncology and radiopharmaceuticals, with accelerated speed to market and potential first-mover advantage in key tumor types creating a multi-billion dollar opportunity and robust long-term earnings growth…"

Bear case: roughly fairly valued

"Bristol-Myers Squibb is facing significant upcoming patent cliffs, especially for blockbusters like Eliquis (generic in 2028) and Opdivo, raising the risk of generic and biosimilar competition, which could materially impact long-term revenue and earnings growth…"

Do you think there's more to the story for Bristol-Myers Squibb? Head over to our Community to see what others are saying!

The Bottom Line

The Discounted Cash Flow (DCF) view suggests Bristol-Myers Squibb screens as undervalued on its long term cash generation, while the earnings multiple points to pricing that is broadly in line with peers. That split reflects two different lenses: the intrinsic value estimate is driven by cash flow timing and investment needs, and the P/E view is anchored in how much growth and risk investors are currently willing to pay for. The key question now is whether Bristol-Myers Squibb can turn its pipeline, partnerships and AI assisted discovery work into durable cash flows before patent and execution risks affect that potential.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.